36 research outputs found

    Lovastatin Modulates Glycogen Synthase Kinase-3β Pathway and Inhibits Mossy Fiber Sprouting after Pilocarpine-Induced Status Epilepticus

    Get PDF
    This study was undertaken to assay the effect of lovastatin on the glycogen synthase kinase-3 beta (GSK-3β) and collapsin responsive mediator protein-2 (CRMP-2) signaling pathway and mossy fiber sprouting (MFS) in epileptic rats. MFS in the dentate gyrus (DG) is an important feature of temporal lobe epilepsy (TLE) and is highly related to the severity and the frequency of spontaneous recurrent seizures. However, the molecular mechanism of MFS is mostly unknown. GSK-3β and CRMP-2 are the genes responsible for axonal growth and neuronal polarity in the hippocampus, therefore this pathway is a potential target to investigate MFS. Pilocarpine-induced status epilepticus animal model was taken as our researching material. Western blot, histological and electrophysiological techniques were used as the studying tools. The results showed that the expression level of GSK-3β and CRMP-2 were elevated after seizure induction, and the administration of lovastatin reversed this effect and significantly reduced the extent of MFS in both DG and CA3 region in the hippocampus. The alteration of expression level of GSK-3β and CRMP-2 after seizure induction proposes that GSK-3β and CRMP-2 are crucial for MFS and epiletogenesis. The fact that lovastatin reversed the expression level of GSK-3β and CRMP-2 indicated that GSK-3β and CRMP-2 are possible to be a novel mechanism of lovatstain to suppress MFS and revealed a new therapeutic target and researching direction for studying the mechanism of MFS and epileptogenesis

    sCT loaded HPbCD/PEG particles : Physicochemical properties and sCT pharmacokinetics after pulmonary delivery

    No full text
    International audiencePurpose: To formulate salmon calcitonin (sCT)-loaded porous microparticles (PMs) using linear or branched PEG and hydroxyl-propyl beta-cyclodextrin (HPbCD) for pulmonary administration.Methods: Mixtures of linear or branched PEG (10kDa) and HPbCD in different weight ratios were spray dried from water-methanol-butyl acetate solutions. PMs were characterised by thermal analysis, X-ray diffraction, dynamic vapour sorption, inverse gas chromatography and SEM. Particle size distributions were determined by laser diffraction. Aerodynamic properties were measured using a next generation impactor. sCT loading was determined by HPLC. sCT apparent permeability was measured across Calu-3 epithelial monolayers. The bioactivity of sCT was measured using a cAMP assay. sCT pharmacokinetics in Wistar rats were evaluated after i.v. bolus injection of a sCT solution and lung insufflation of the formulations or sCT solution.Results: Particle size distributions showed little change with changes in the HPbCD/PEG ratio, however, particle morphology, surface properties and PEG crystallinity were altered. Increasing the amount of HPbCD above a HPbCD/PEG ratio of 1/1 led to increases in the PMs’ surface roughness, the dispersive contribution of the particles’ surface energy, the water uptake capacity and PEG amorphisation. These changes in particle properties influenced their aerodynamic behaviour. PMs with the highest surface energy and hygroscopicity produced the lowest fine particle fraction and largest MMAD. For all formulations, sCT loading efficiency was around 100%. All formulations containing PEG were able to maintain complete bioactivity of sCT, however, bioactivity decreased to 60% when sCT was processed with HPbCD alone. This formulation demonstrated a significant increase in sCT apparent permeability across Calu-3 monolayer. The relative sCT bioavailability in comparison to the nebulised solution was higher for linear PEG based particles (180%) than for particles made of branched PEG (126%).Conclusion: Using different types of PEG and HPbCD in different proportions allowed microparticles to be formulated with different physicochemical properties leading to different pharmacokinetics profiles of sCT after inhalation. Bioavailability of sCT after lung insufflation of particles was significantly higher than for the pure solution. This work was funded by a Strategic Research Cluster grant (07/SRC/B1154) under the National Development Plan co-funded by EU Structural Funds and Science Foundation Ireland
    corecore